EMA gets to work on bringing more advanced therapies to market
This article was originally published in RAJ Devices
Executive Summary
The European Medicines Agency's Committee for Advanced Therapies will look at how the regulatory framework around advanced therapies such as gene therapy and regenerative medicine can be made more accessible for small and medium-sized firms, academia, patient groups, hospitals, charity foundations and trusts that develop advanced therapies1,2. The EMA admits that the current framework is very complex and that many SMEs and academics lack the financial and human resources to negotiate it. Often developers do not have the resources to bring their products, which are sometimes fairly mature, to regulatory standards, says the EMA.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.